Hyaluronic Acid Filler Injection Research Articles

Use of hyaluronic acid filler and botulinum toxin type A in facial renjuvenation

Background Facial soft tissue augmentation and rejuvenation have become over the past several years the practice more requested in aesthetic medicine. The authors share their experiences to evaluate long term safety, clinical effectiveness and patient satisfaction regarding the injection of hyaluronic acid (HA) filler and botulinum toxyn tipe A (BTTA). In some cases the patient received a combined treatment of HA and BTTA to obtain absolute aestethic satisfaction.

The potpourri approach to hyaluronic acid filler injections

There is an ever-expanding range of hyaluronic acid fillers with varying physical characteristics available to cosmetic dermatologists. These fillers are commercially packaged in syringes of approximately 1 mL (range 0.5-2 mL) volume. Filler injectors are currently qualitatively and quantitatively restricted to fillers packaged in ready-to-go syringes. Patients often present for pan-facial rejuvenation requiring varying amounts of fillers as well as more than one type/subtype of filler for optimum correction. The potpourri approach allows access to a range of prepared hyaluronic acid filler subtypes that can be used on the same patient in the one session. The potpourri method centres on the use of multiple 31-gauge insulin syringes prepared with a range of different hyaluronic acid filler products that are ready for use. This increases flexibility with filler selection and has the potential to provide better filler-to-tissue match for patients.

Effect of Multisyringe Hyaluronic Acid Facial Rejuvenation on Perceived Age

The objective of aesthetic treatments is to create a more youthful appearance. Most injectable fillers are indicated for the reduction of nasolabial folds, but the current aesthetic movement is toward volume replacement in multiple areas, known as global fillers or liquid face-lift. To quantify the degree of perceived age reduction from multisyringe hyaluronic acid treatment. Ten women were treated with 6 to 8 mL of hyaluronic acid. Exclusion criteria were no laser for 6 months and no hyaluronic acid fillers for 6 months or semipermanent fillers for 1 year. High-resolution photographs were taken in identical lighting and position before and 2 and 4 weeks after treatment. Three blinded dermatologists rated patients' ages before and after from photographs. The dermatologists reported an average of 6.1 to 7.3 years of reduction in apparent age at 2 and 4 weeks, respectively. The patients perceived a decrease in apparent age of 7.8 and 9 years. Multisyringe injection of hyaluronic acid filler into the aging face results in a reduction of apparent age from 6.1 to 9 years after 2 to 4 weeks. Full-face correction with hyaluronic acid is an important procedure in the armamentarium of anti-aging techniques.

Letter: Foreign Body Reaction to Hyaluronic Acid Filler Injection: In Search of an Etiology

Letter: Foreign Body Reaction to Hyaluronic Acid Filler Injection: In Search of an Etiology

Reversible vs. nonreversible fillers in facial aesthetics: Concerns and considerations

Soft-tissue augmentation of the face is an increasingly popular cosmetic procedure. In recent years, the number of available filling agents has also increased dramatically, improving the range of options available to physicians and patients. Understanding the different characteristics, capabilities, risks, and limitations of the available dermal and subdermal fillers can help physicians improve patient outcomes and reduce the risk of complications. The most popular fillers are those made from cross-linked hyaluronic acid (HA). A major and unique advantage of HA fillers is that they can be quickly and easily reversed by the injection of hyaluronidase into areas in which elimination of the filler is desired, either because there is excess HA in the area or to accelerate the resolution of an adverse reaction to treatment or to the product. In general, a lower incidence of complications (especially late-occurring or long-lasting effects) has been reported with HA fillers compared with the semi-permanent and permanent fillers. The implantation of nonreversible fillers requires more and different expertise on the part of the physician than does injection of HA fillers, and may produce effects and complications that are more difficult or impossible to manage even by the use of corrective surgery. Most practitioners use HA fillers as the foundation of their filler practices because they have found that HA fillers produce excellent aesthetic outcomes with high patient satisfaction, and a low incidence and severity of complications. Only limited subsets of physicians and patients have been able to justify the higher complexity and risks associated with the use of nonreversible fillers.

Nonsurgical Treatment of Cicatricial Ectropion with Hyaluronic Acid Filler

Cicatricial lower eyelid ectropion is caused by a shortening of the anterior lamella, with resultant eversion of the eyelid away from the globe. Treatment is typically surgical; however, the author hypothesized that a nonsurgical injection of hyaluronic acid filler could stretch the tethered skin and act as a tissue expander to correct the lid. Fifteen patients with lower eyelid cicatricial ectropion were injected with a hyaluronic acid filler below the surface of the affected eyelid skin. The patients were followed prospectively for over 1 year for outcomes and complications. All patients achieved immediate and dramatic correction of their ectropion with a single injection. Eleven patients (73 percent) had complete correction lasting more than 1 year and four had partial correction. No major complications were observed; however, temporary bruising and a Tyndall effect was evident in a majority of patients. Hyaluronic acid filler injections can successfully treat cicatricial ectropion by expanding the tethered anterior lamella of the skin. This provides an effective alternative to surgical correction of the lid. The treatment is quick, safe, and easy to learn.

Persistent delayed‐type hypersensitivity reaction to injectable non‐animal‐stabilized hyaluronic acid

Injectable hyaluronic acid is a glycosaminoglycan used for soft-tissue augmentation. A number of products that are not Food and Drug Administration (FDA) approved for use in the United States are used commonly in Europe. We report a case of persistent delayed-type hypersensitivity to injected non-animal-stabilized hyaluronic acid. The patient was initially injected in Europe with a non-FDA-approved filler but traveled to the United States for evaluation of this adverse reaction. A case of adverse reaction to non-animal-stabilized hyaluronic acid is described. An overview of selected hyaluronic acid filler products is provided. The patient developed persistent facial edema after injection of hyaluronic acid filler to the melolabial folds, glabella, lips, and perioral rhytids. Injectable hyaluronic acid can be associated with a variety of complications including immediate and delayed-type hypersensitivity reactions. Physicians should be familiar with products used in other countries, as patients may present for evaluation following adverse reaction to fillers obtained abroad or from American physicians using non-FDA-approved products.

Effects of prostaglandins E1, E2, A1, and F1-alpha on isolated vascular smooth muscle

Effects of prostaglandins E1, E2, A1, and F1-alpha on isolated vascular smooth muscle